Anonymous User
Login / Registration

Gastroenterologie
a hepatologie

Gastroenterology and Hepatology

Gastroent Hepatol 2012; 66(1): 32-36.

Serum levels of infliximab and antibodies to infliximab, clinical using

Laura Gombošová Orcid.org  1, Mária Zakuciová Orcid.org  2, Erika Barlová Orcid.org  3, Lucia Novotná Orcid.org  3, Eduard Veseliny Orcid.org  4

+ Affiliation

Summary

Timely diagnosing, precise treatment and the individual approach are needed for complex management of patients with inflammatory bowel diseases. The goal of the complex and individual approach is to achieve and maintain the remission and to minimize the complications. Tumor necrosis factor alpha (TNF-α) is the key cytokine of the chronic bowel inflammation. Infliximab is the longest used biologic compound. Infliximab reduces TNF-α levels, regulates inflammation and induces remission. Monitoring of the infliximab levels and antibodies to infliximab can contribute to optimalization of the biological therapy and tailoring to individual cases. Loss of response can be also caused by undetectable levels or positive antibodies to infiximab.

Keywords

Crohn’s disease, pharmacokinetics, infliximab, ulcerative colitis

To read this article in full, please register for free on this website.

Benefits for subscribers

Benefits for logged users

Credited self-teaching test